Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin

References

• National Cancer Institute SEER (Surveillance, Epidemiology, and End Results) Cancer Statistics Review 1975–2002 [on-line]. Available from URL: http://seer.cancer.gov
   Google Scholar
• BaerMRGeorgeSLDodgeRKPhase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720Blood200210041224123212149202
   PubMed Web of Science ®Google Scholar
• GodwinJEKopeckyKJHeadDRA double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031)Blood19989110360736159572995
   PubMed Web of Science ®Google Scholar
• LowenbergBSuciuSArchimbaudEMitoxantrone versus daunorubicin in induction-consolidation chemotherapy–the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon GroupJ Clin Oncol19981638728819508168
   PubMed Web of Science ®Google Scholar
• MayerRJDavisRBSchifferCAIntensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group BN Engl J Med1994331148969038078551
   PubMed Web of Science ®Google Scholar
• RoweJMNeubergDFriedenbergWA phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology GroupBlood2004103247948514512295
   PubMed Web of Science ®Google Scholar
• StoneRMBergDTGeorgeSLGranulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group BN Engl J Med199533225167116777760868
   PubMed Web of Science ®Google Scholar
• ByrdJCMrozekKDodgeRKPretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)Blood20021004325433612393746
   PubMed Web of Science ®Google Scholar
• LowenbergBvan PuttenWTheobaldMEffect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemiaN Engl J Med2003349874375212930926
   PubMed Web of Science ®Google Scholar
• GoldstoneAHBurnettAKWheatleyKSmithAGHutchinsonRMClarkREAttempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trialBlood20019851302131111520775
   PubMed Web of Science ®Google Scholar
• StoneRMBergDTGeorgeSLPostremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabineBlood200198354855311468148
   PubMed Web of Science ®Google Scholar
• RoweJMNeubergDFriedenbergWA phase 3 study of three induction regimens and of priming with GM-CSF in older adults with AML: A trial by the Eastern Cooperative Oncology GroupBlood200410347948514512295
   PubMed Web of Science ®Google Scholar
• GoldstoneAHBurnettAKWheatleyKAttempts to improve treatment outcomes in AML in older patients: The results of the United Kingdom Medical Research Council AML11 trialBlood2001981302131111520775
   PubMed Web of Science ®Google Scholar
• AndersonJEKopeckyKJWillmanCLOutcome after induction chemotherapy for older patients with AML is not improved with mitoxantrone and etoposide compared to daunorubicin and cytarabine: A Southwest Oncology Group StudyBlood20021003869387612393614
   PubMed Web of Science ®Google Scholar
• Van der HoltBLowenbergBBurnettAKThe value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated AML in relation to MDR1 status at diagnosisBlood20051062646265415994288
   PubMed Web of Science ®Google Scholar
• SchlenkRFDohnerKKrauterJMutations and treatment outcome in cytogenetically normal acute myeloid leukemiaN Engl J Med20083581909191818450602
   PubMed Web of Science ®Google Scholar
• United States Census BureauUS Interim Projections by Age, Sex, Race, and Hispanic Origin http://wwwcensusgov/ipc/www/usinterimproj. 2004. Internet release date March 182004
   Google Scholar
• BloomfieldCDLawrenceDByrdJCFrequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtypeCancer Res19985818417341799751631
   PubMed Web of Science ®Google Scholar
• GrimwadeDWalkerHOliverFThe importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial The Medical Research Council Adult and Children’s Leukaemia Working PartiesBlood1998927232223339746770
   PubMed Web of Science ®Google Scholar
• GrimwadeDWalkerHHarrisonGThe predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trialBlood20019851312132011520776
   PubMed Web of Science ®Google Scholar
• LeithCPKopeckyKJGodwinJAcute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group studyBlood1997899332333299129038
   PubMed Web of Science ®Google Scholar
• TillyHCastaigneSBordessouleDLow-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderlyJ Clin Oncol1990822722792299370
   PubMed Web of Science ®Google Scholar
• BuchnerTBerdelWEHaferlachCOlder age is an independent risk factor in AML. ASH Annual Meeting Abstracts2008112555
   Google Scholar
• FaragSArcherKMrózekKPre-treatment cytogenetics predict complete remission and long-term outcome in patients (Pts) 60 years with acute myeloid leukemia (AML): results from Cancer and Leukemia Group B (CALGB) 8461Blood2004104568 [abstract].
   Web of Science ®Google Scholar
• SekeresMAElsonPWangXTime from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patientsBlood2009113283618827183
   PubMed Web of Science ®Google Scholar
• LowenbergBZittounRKerkhofsHOn the value of remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia GroupJ Clin Oncol19897126812742475589
   PubMed Web of Science ®Google Scholar
• BazRRodriguezCFuAZImpact of remission induction chemotherapy on survival in older adults with acute myeloid leukemiaCancer20071101752175917724726
   PubMed Web of Science ®Google Scholar
• FerraraFAnnunziatMCopiaCMagrinSMeleGMirtoSTherapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemiaHaematologica1998831261319549923
   PubMed Web of Science ®Google Scholar
• BurnettAKMilliganDPrenticeAGA comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatmentCancer200710961114112417315155
   PubMed Web of Science ®Google Scholar
• JilaniIEsteyEHuhYDifferences in CD33 intensity between various myeloid neoplasmsAm J Clin Pathol200211856056612375643
   PubMed Web of Science ®Google Scholar
• BradleyJMDowellJAKingSPLiuHBergerMSMylotarg Study GroupImpact of age and gender on the pharmacokinetics of gemtuzumab ozogamicinPharmacotherapy2001211175118011601662
   PubMed Web of Science ®Google Scholar
• SieversELAppelbaumFRSpielbergerRTSelective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of anti-CD33 calicheamicin immunoconjugateBlood1999933678368410339474
   PubMed Web of Science ®Google Scholar
• SieversELLarsonRAStadtmauerEAMylotarg Study GroupEfficacy and safety of gentuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapseJ Clin Oncol2001193244325411432892
   PubMed Web of Science ®Google Scholar
• LarsonRASieversELStadtmauerEAFinal report of efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first recurrenceCancer20051041442145216116598
   PubMed Web of Science ®Google Scholar
• LeopoldLHBergerMSChengSCCortesJGilesFEsteyEComparative efficacy and safety of gemtuzumab ozogamicin mono-therapy and high-dose cytarabine combination therapy in the treatment of patients with acute myeloid leukemia in first relapseClin Adv Hematol Oncol2003111211816224390
   PubMedGoogle Scholar
• TsimberidouACortesJThomasDGemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemiaLeuk Res20032789389712860008
   PubMed Web of Science ®Google Scholar
• StoneRMMoserBSchulmanPA dose escalation and phase II study of Gemtuzumab Ozogamicin (GO) with high-dose cytarabine (HiDAC) for patients with refractory or relapsed acute myeloid leukemia; CALGB 19902Blood2004104 Abstr 873.
   Web of Science ®Google Scholar
• DoyenJItalianoAPeyradeFBouyerCThyssAGemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukemiaBrit J Haem2008141734747
   Web of Science ®Google Scholar
• FianchiLPaganoLLeoniFGemtuzumab, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemiaAnn Oncol20081912813417906298
   PubMed Web of Science ®Google Scholar
• ChevallierPDelaunayJTurlurePLong-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33+ primary resistant or relapsed acute myeloid leukemiaJ Clin Oncol200826325192519718854573
   PubMed Web of Science ®Google Scholar
• NabhanCRundhaugenLRileyMPhase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or olderLeuk Res20042890991915234567
   PubMed Web of Science ®Google Scholar
• AmadoriSSuciuSStasiRGemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organization for Research and Treatment of Cancer and Gruppo Italiano Malattie Emattologiche dell’Adulto Leukemia GroupsLeukemia2005191768177316079891
   PubMed Web of Science ®Google Scholar
• EsteyEThallPFGilesFJGemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosideBlood2002994343434912036860
   PubMed Web of Science ®Google Scholar
• ClavioMVignoloLAlbarelloAAdding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patientsBr J Haematol200713818619517593025
   PubMed Web of Science ®Google Scholar
• NandSGodwinJSmithSHydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trialLeuk Lymphoma200849112141214719021057
   PubMed Web of Science ®Google Scholar
• Lo-CocoFCiminoGBrecciaMGemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemiaBlood20041041995199915187030
   PubMed Web of Science ®Google Scholar
• EsteyEHGilesFJBeranMExperience with gemtuzumab ozogamycin (mylotarg) and all-trans retinoic acid in untreated acute promyelocytic leukemiaBlood2002994222422412010830
   PubMed Web of Science ®Google Scholar
• EsteyEGarcia-ManeroGFerrajoliAUse of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemiaBlood20061073469347316373661
   PubMed Web of Science ®Google Scholar
• AribiAKantarjianHMEsteyEHCombination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemiaCancer20071091355135917326049
   PubMed Web of Science ®Google Scholar
• AmicoDBarbuiAMErbaERambaldiAIntronaMGolayJDifferential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin (Mylotarg®) in vitro. Role of Chk1 and Chk2 phosphorylation and caspase 3Blood2003101114589459712576328
   PubMed Web of Science ®Google Scholar
• WalterRBGooleyTAvan der VeldenVHJCD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapyBlood20071094168417017227830
   PubMed Web of Science ®Google Scholar
• van der KolkDMde VriesEGEMullerMVellengaEThe role of drug efflux pumps in acute myeloid leukemiaLeuk Lymphoma20024368570112153153
   PubMed Web of Science ®Google Scholar
• PiccalugaPPMartinelliGRondoniMGemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomasLeuk Lymphoma20044591791179515223637
   PubMed Web of Science ®Google Scholar
• CortesJTsimberidouAAlvarezRMylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemiaCancer Chemother Pharmacol20025049750012451477
   PubMed Web of Science ®Google Scholar
• AlvaradoYTsimberidouAKantarjianHPilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemiaCancer Chemother Pharmacol200351879012497211
   PubMed Web of Science ®Google Scholar
• TaksinALLegrandORaffouxEde RevelTHigh efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alpha groupLeukemia200721667117051246
   PubMed Web of Science ®Google Scholar